Citarinostat
- Generic Name
- Citarinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26ClN5O3
- CAS Number
- 1316215-12-9
- Unique Ingredient Identifier
- 441P620G3P
- Background
Citarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02886065
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath